Biogen's oral dimethyl fumarate shows MS lesion reduction
This article was originally published in Scrip
Executive Summary
Biogen Idec's experimental oral drug dimethyl fumarate (BG-12, BG00012) has reduced new gadolinium enhancing inflammatory brain lesions in patients with relapsing-remitting multiple sclerosis (MS) by up to 69% compared with placebo, according to publication of Phase II results in the October 25th issue of The Lancet.